Work in Progress
A look at the seven new research projects funded in 2006/07 and why we need your help
Here is a short summary of all of the vital projects you have helped to fund in 2006 and 2007. Thanks to your support, we are able to conduct medical research into many aspects of prostate cancer, including improved diagnosis and new treatments.
A novel prognostic marker of prostate cancer
Professor Mustafa Djamgoz at Imperial College has been awarded £51,574 to research a gene that might be important in the early identification of aggressive prostate cancer, and also in creating a longlasting treatment for it.
The needs of carers
Paul Sinfield works at Leicester University and has been awarded £83,564 to research the support and information needs of carers for men with prostate cancer.
New targets for therapy in prostate cancer
Professor Hing Leung works at the Beatson Cancer Centre in Glasgow and has been awarded £73,690 to begin developing a possible drug treatment for aggressive prostate cancer.
Gene therapy
Dr Munitta Muthana works at Sheffield University and has been awarded £210,564 to research a gene therapy for advanced prostate cancer.
Identification of aggressive cancers
Dr Chris Parker works at the Institute of Cancer Research in Sutton and has been awarded £158,635 to look for biomarkers – used to indicate the effects or progress of a disease or condition – that will help predict how individuals might be affected by their prostate cancer. The results will help doctors target life-saving treatment on men who need it and avoid treatment side effects in men who do not need a ‘life-saving’ intervention because their lives are not in danger.
Improving therapies and treatment
Dr Dmitry Pshezhetskiy works at Imperial College and has been awarded £118,893 to research a molecule that might make prostate cancer cells more susceptible to both chemotherapy and radiotherapy.
New target to prevent spread of prostate cancer to the bone
Dr Justin Sturge works at Imperial College and has been awarded £97,093 to study a molecule which might be a potential target for treatments that stop prostate cancer spreading to the bone.
Keeping medical research relevant
Robert Oldroyd, Research Advisory Committee member
“Our role is to make sure the research The Prostate Cancer Charity funds makes a specific difference to men's lives. The key thing for me is to discover why prostate cancer occurs, because if we can find that out, it will eventually avoid the need for all the other stuff down the line.”
back: 1 in 11 | next: Real Stories